Yatai Pharmaceuticals' net profit attributable to shareholders reached 96 million yuan in 2025, marking a year-on-year increase of 181.27%. Non-recurring gains accounted for over 167% of total profits, driving the overall earnings.

The company's revenue for 2025 decreased by 20.25% year-on-year, with a net loss after deducting non-recurring items of 0.65 billion yuan, representing a year-on-year decline of 129.94%. The core business continues to face significant pressure. However, the net profit attributable to shareholders surged by 181.27% to 0.96 billion yuan, primarily driven by non-recurring gains such as 1.49 billion yuan from equity disposals, accounting for a staggering 167.17%. Operating cash flow increased by only 18.66%, significantly lower than the growth rate of net profit, highlighting the 'paper prosperity' of its performance. The recovery of the core business and breakthroughs in internationalization remain to be observed.

lanjinger.comApr 25 17:07

Asia-Pacific Pharmaceutical: 2025 Annual Report

SZSIApr 25 00:00 · Announcements

Asia-Pacific Pharmaceutical: Summary of the 2025 Annual Report

SZSIApr 25 00:00 · Announcements

Asia-Pacific Pharmaceutical: First Quarter Report for 2026

SZSIApr 25 00:00 · Announcements

Express News | Asia-Pacific Pharmaceutical: Net profit of 96.3078 million yuan in 2025, up 181.27% year-on-year

BreakingsApr 24 23:37

Express News | Asia-Pacific Pharmaceuticals: Net loss of 2.5875 million yuan in the first quarter

BreakingsApr 24 23:36